Mechanistic model of chimeric antigen receptor T cell activation 

Modulation of T cell responses by extracellular nucleotides 

Phospho-proteomic analysis of immune cell activation 

Characterizing the protein expression of S1P receptors in T-cell acute lymphoblastic leukemia (T-ALL) cell lines 

Novel design and combinatory therapy to enhance chimeric antigen receptor engineered T cells (CAR-T) efficacy against solid tumor 

Interaction of epigenetics and SMAD signaling in stem cells and diseases 

The role of CD99 in T cells 

Lym-1 epitope targeted chimeric antigen receptor (CAR) T cells for the immunotherapy of cancer 

Generation and characterization of fully human anti-CD19 chimeric antigen receptor T (CAR-T) cells for the treatment of hematologic malignancies 

The immunomodulatory effects of midostaurin on T cells 

Development of an NFAT-GFP Jurkat T cell reporter system for acceleration of T Cell receptor affinity screening 

Understanding the impact of cell-to-cell variability on intracellular signaling in CAR cells through mathematical modeling 

Y-shaped DNA based pMHC nonamers for detecting low-affinity T cells 

Pre-B cell receptor signaling in acute lymphoblastic leukemia 

Modulation of human tumor antigen-specific T cell responses by programmed death-1 blockade 

Tri-specific T cell engager immunotherapy targeting tumor initiating cells 

Investigating the effects of T cell mediated anti-leukemia activity in FLT3-ITD positive acute myeloid leukemia 

Role of FGFR2b signaling pathway in the development of ectodermal derivatives 

Improving antitumor efficacy of chimeric antigen receptor-engineered immune cell therapy with synthetic biology and combination therapy approaches 

Suppressor cell therapy: targeting T regulatory cells in cancer 

Engineering viral vectors for T-cell immunotherapy and HIV-1 vaccine 

Self-secretion of checkpoint blockade enhances antitumor immunity by murine chimeric antigen receptor-engineered T cells 

Engineering chimeric antigen receptor (CAR) -modified T cells for enhanced cancer immunotherapy 

Enhancing the anti-cancer specificity of chimeric antigen receptor T cells through targeting HLA loss 

Tri-specific T cell engager immunotherapy targeting tumor initiating cells